Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2025, Teva Pharmaceutical Industries Ltd. (TEVA) reported revenue of $4.18 billion, up 0.3% over the same period last year. EPS came in at $0.66, compared to $0.61 in the year-ago quarter.The reported revenue represents a surprise of -2.47% over the Zacks Consensus Estimate of $4.28 billion. With the consensus EPS estimate being $0.63, the EPS surprise was +4.76%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Geographic Revenue- Europe: $1.3 billion versus the five-analyst average estimate of $1.25 billion. The reported number represents a year-over-year change of +7%.Geographic Revenue- International Markets: $495 million compared to the $602.4 million average estimate based on five analysts. The reported number represents a change of -16.5% year over year.Geographic Revenue- United States: $2.15 billion versus $2.19 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +1.9% change.Geographic Revenue- United States- Anda: $365 million versus the four-analyst average estimate of $358.28 million. The reported number represents a year-over-year change of -2.1%.Geographic Revenue- Europe- COPAXONE: $50 million versus the four-analyst average estimate of $40.5 million. The reported number represents a year-over-year change of -5.7%.Geographic Revenue- Europe- Respiratory products: $55 million versus $55.07 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -3.5% change.Geographic Revenue- International Markets- Generic products: $410 million versus the four-analyst average estimate of $478.57 million. The reported number represents a year-over-year change of -15.6%.Geographic Revenue- International Markets- COPAXONE: $7 million versus $10.83 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -50% change.Geographic Revenue- United States- AJOVY: $63 million compared to the $50.8 million average estimate based on four analysts. The reported number represents a change of +50% year over year.Revenue- COPAXONE- Total: $119 million versus $101.85 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -19.6% change.Revenue- Other- Total: $232 million versus $259.03 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +118.9% change.Revenue- API sales to third parties: $135 million versus $156.49 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -10.6% change.View all Key Company Metrics for Teva Pharmaceutical Industries here>>>Shares of Teva Pharmaceutical Industries have returned -0.6% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.#1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks